Pharmaceuticals company Dr. Reddy's Laboratories announced Q1FY26 results Revenues: Rs 85,452 million, change Up by 11 % YoY. EBITDA: Rs 22,784 million, with Margin of 26.7% of Revenues. Profit before Tax: Rs 19,047 million, change Up by 1 % YoY; Down by 5% QoQ. Profit after Tax: Rs 14,178 million attributable to Equity Holders, Up: 2% YoY; Down 11 % QoQ. G V Prasad, Co-Chairman & MD, said: "We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio. The pricing pressure on Lenalidomide is expected to intensify in the U.S. generics market. We remain focused on strengthening our base business by delivery of our pipeline assets, improving overall productivity and business development." Result PDF